Kyle Johnson, MD
Psychiatry · Morrilton, ARNPI 1730307570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,560 of the $68,746 with a category attached, or 95.4%. AbbVie accounts for 98.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $26,701 and has fallen 99.3% since, to $187 in 2025. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $375.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$67K
- Johnson & Johnson$213
- Takeda Pharmaceuticals U.S.A., Inc.$126
- Otsuka America Pharmaceutical, Inc.$122
- Myriad Genetic Laboratories, Inc.$121
- Sunovion Pharmaceuticals Inc.$97
- plus $614 from 11 others
What the payments were for
- Speaking & faculty fees$65,56095%
- Travel & lodging$1,3892%
- Food & beverage$1,7903%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $67,454 |
| Johnson & Johnson | 16 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $126 |
| Otsuka America Pharmaceutical, Inc. | 7 | $122 |
| Myriad Genetic Laboratories, Inc. | 1 | $121 |
| Sunovion Pharmaceuticals Inc. | 8 | $97 |
| Urogen Pharma, Inc. | 4 | $94 |
| Neurocrine Biosciences, Inc. | 7 | $93 |
| Alkermes, Inc. | 4 | $92 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Lundbeck LLC | 4 | $62 |
| Merck | 4 | $47 |
| Sun Pharmaceutical Industries Inc. | 1 | $47 |
| Avanir Pharmaceuticals, Inc. | 3 | $37 |
| Shire North American Group Inc | 3 | $36 |
| Neuronetics, Inc. | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,746 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $334 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Morrilton
- Leslie SmithLittle Rock$766K
- Tad TillemansLittle Rock$656K
- Steven KoryElm Springs$628K
- Ronald WautersSearcy$204K
- Herman ClementsSearcy$187K
- Randal ScholmaLowell$111K
- Paul WylieLittle Rock$54K
- Angela ChapmanFayetteville$40K
- Joann KirchnerNorth Little Rock$39K
- Margaret WeissLittle Rock$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.